Concordance of HER2 Immunohistochemistry and Fluorescence Hybridization Using Tissue Microarray in Breast Cancer
Overview
Authors
Affiliations
Aim: Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are common methods for assessment of human epidermal growth factor receptor 2 (HER2) in breast cancer.
Materials And Methods: In a cohort of 498 consecutive patients with breast cancer, we examined concordance between IHC and FISH for HER2 on tissue microarray (TMA) sections. In a subset of 116 specimens, we examined HER2 concordance from the block used for diagnostics and a randomly-chosen additional block (a proxy of the core biopsy).
Results: Overall concordance between both methods on TMA sections was 93.8% and between HER2, determined on diagnostic and additional blocks, was 93.6% for IHC and 98.0% for FISH.
Conclusion: Since some cases were discordant, we suggest that both methods be used for HER2 assessment. The lower concordance rate between diagnostic and additional blocks using IHC compared to FISH suggests a greater variability of IHC staining across tumor regions than for FISH results.
Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes.
Franchina M, Pizzimenti C, Fiorentino V, Martini M, Ricciardi G, Silvestris N Int J Mol Sci. 2023; 24(16).
PMID: 37628975 PMC: 10454084. DOI: 10.3390/ijms241612795.
The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer.
Bragina O, Deyev S, Chernov V, Tolmachev V Acta Naturae. 2022; 14(2):4-15.
PMID: 35923562 PMC: 9307982. DOI: 10.32607/actanaturae.11611.
Page R, Patil D, Akolkar D, Murthy S, Bendale K, Patil R PLoS One. 2022; 17(6):e0270139.
PMID: 35714131 PMC: 9205490. DOI: 10.1371/journal.pone.0270139.
Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
Burguin A, Furrer D, Ouellette G, Jacob S, Diorio C, Durocher F PLoS One. 2020; 15(6):e0234991.
PMID: 32584853 PMC: 7316326. DOI: 10.1371/journal.pone.0234991.
A review on methods for diagnosis of breast cancer cells and tissues.
He Z, Chen Z, Tan M, Elingarami S, Liu Y, Li T Cell Prolif. 2020; 53(7):e12822.
PMID: 32530560 PMC: 7377933. DOI: 10.1111/cpr.12822.